Physician profile
Ken Arakawa
NPI 1558334888
$3,200.84
in general payments reported to CMS, 2019-2025
18 companies · $588 in 2025
The $588 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2020: $286 · 2021: $347 · 2022: $151 · 2023: $413 · 2024: $611 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,044.48 | 2019-2025 | Krystexxa, Uplizna, Evenity |
| Abbvie INC. | $462.77 | 2020-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $455.74 | 2019-2025 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $203.03 | 2019-2022 | |
| Pfizer INC. | $201.02 | 2019-2022 | |
| Genentech USA, INC. | $197.45 | 2019-2023 | Actemra |
| Glaxosmithkline, LLC. | $183.50 | 2020-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $150.11 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $91.12 | 2019-2024 | |
| Lilly USA, LLC | $36.56 | 2019-2023 | Taltz |
| Radius Health, INC. | $31.80 | 2019 | |
| Gilead Sciences, INC. | $28.48 | 2019 | |
| Genzyme Corporation | $23.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.25 | 2023 | Saphnelo |
| Arcutis Biotherapeutics, INC. | $19.35 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $19.18 | 2019 | |
| Janssen Biotech, INC. | $15.99 | 2025 | Tremfya |
| Mallinckrodt Enterprises LLC | $14.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ken Arakawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.